This Annual Performance Plan (APP) for the 2023/24 financial year that has been developed by SAHPRA, represents the planned actions of the Board of SAHPRA to ensure that through their considered and responsible actions, they can, together with the staff at the Authority, assure and...
This guide is intended to provide guidance to applicants on Good Review Practices. It represents the South African Health Products Regulatory Authority’s current thinking on the safety, quality and efficacy of medicines and the safety, quality and performance of medical devices. It is not intended...
Please note that the South African Health Products Regulatory has hereby extended the deadline date for comments on the Borderline Products guideline (SAHPGL-CRO-01) from the 5th of September 2022, to the 8th of November 2022....
Business-As-Usual (BAU) is in the process of verifying submitted/received new medicine and variation applications. Industry is kindly requested to verify/confirm if all the applications that have been submitted to SAHPRA via BAU are being processed....
In keeping with SAHPRA’s strategic objectives – Digital Transformation has been a key focus are for SAHPRA ICT....
The Minister Of Health, In Consultation With The Minister Of Finance And SAHPRA, In Terms Of Section 35 (1) (Xxi) And (Xxxii) Read Together With Section 35(4) Of The Medicines And Related Substances, Made Regulations In The Schedule....